Analysis of the Main Checkpoints of the JNK-MAPK Pathway in HTLV-1-Associated Leukemia/Lymphoma via Boolean Network Simulation.
Autor: | Mardi S; Student Research Committee, Arak University of Medical Sciences, Arak, Iran., Letafati A; Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran., Hosseini A; Department of Computer Engineering, Faculty of Engineering, Raja University, Qazvin, Iran., Faraji R; Department of Animal Sciences, College of Agriculture & Natural Resources, University of Tehran, Karaj, Iran., Hosseini P; Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran., Mozhgani SH; Noncommunicable Disease Research Center, Alborz University of Medical Sciences, Karaj, Iran. hamidrezamozhgani@gmail.com.; Department of Microbiology and Virology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran. hamidrezamozhgani@gmail.com. |
---|---|
Jazyk: | angličtina |
Zdroj: | Biochemical genetics [Biochem Genet] 2024 Sep 25. Date of Electronic Publication: 2024 Sep 25. |
DOI: | 10.1007/s10528-024-10916-0 |
Abstrakt: | The c-Jun N-terminal kinase (JNK) pathway is a signal transduction pathway that plays a critical role in cell growth and survival. Its dysregulation is related to various cancers, including adult T-cell leukemia/lymphoma (ATLL), an aggressive peripheral T-cell malignancy caused by human T-cell lymphotropic virus type 1 (HTLV-1) infection. There is currently no vaccine or definitive treatment for ATLL. This research aimed to identify the JNK-MAPK pathway checkpoints to identify possible therapeutic targets using Boolean network analysis. First, the genes involved in the JNK pathway and their interactions were identified and mapped. Next, a Boolean network analysis was performed using the R programming language, which suggested protein kinase B (AKT) and MAP kinase phosphatase (MKP) for further evaluation. Finally, to confirm the effect of these two genes, a clinical study was conducted among ATLL patients and healthy individuals. The quantitative real time polymerase chain reaction (qRT‒PCR) results revealed a statistically significant decrease in the expression of AKT and MKP in ATLL patients compared to normal controls. This highlights the potential role of these two genes as potential therapeutic targets in ATLL. (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.) |
Databáze: | MEDLINE |
Externí odkaz: |